Schizophrenia in a Molecular Age
Edited by Carol A. Tamminga, M.D.
Series Editors: John M. Oldham, M.D., M.S., and Michelle B. Riba, M.D., M.S.
- 204 Pages
- Editorial Reviews
- ISBN 978-0-88048-961-4
- Item #8961
Schizophrenia is a disease with unknown pathophysiology and etiology. Until recently, what was best known about this disease was derived from clinical observations. Preclinical neuroscience is flourishing with discoveries and advances in all areas of brain function, particularly the cellular and the molecular.
As a way to explain the pathophysiology of schizophrenia, Schizophrenia in a Molecular Age reviews neuroscience mechanisms and analyzes genetic determinants. This book presents:
- A dimensional model of schizophrenia phenomenology that groups schizophrenia phenotypes into three groups: a reality distortion syndrome, a disorganization syndrome, and a psychomotor poverty syndrome
- Evidence for the neurobiologic basis of the cognitive impairments in schizophrenia
- New and evolving techniques of functional brain imaging and what they can tell us about normal brain function and its pathology
- Data on the anatomic units of cognition and correlates with gene and protein units
- The molecular mechanisms of antipsychotic drug action and the group of new antipsychotics
- New treatments to offer, including medications, and psychological and psychosocial interventions, which are significantly better than previous treatment options
The new molecular age presents an exciting opportunity for schizophrenia research. This book is a helpful tool for clinicians in gaining a fuller understanding of schizophrenia. It previews future advances in the pathophysiology of schizophrenia.
Foreword. The multidimensional phenotype of schizophrenia. Implications of early sensory processing and subcortical involvement for cognitive dysfunction in schizophrenia. Functional neuroimaging in schizophrenia: symptom, treatment, and etiology. Disruption of information flow within cortical-limbic circuits and the pathophysiology of schizophrenia. Molecular biology and antipsychotic medications. Index.
About the Authors
Carol A. Tamminga, M.D., is Chief of the Inpatient Program at the Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland in Baltimore, Maryland.
I appreciated the clarity of each single chapter, which was self-sufficient but perfectly integrated in a continuum with the rest of the book. . . . A valuable book for researchers working in biological, and not only biological, research on schizophrenia.—Paola Dazzan, Institute of Psychiatry, London, United Kingdom